Literature DB >> 10961655

Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506.

M Mogi1, A Togari, K Tanaka, N Ogawa, H Ichinose, T Nagatsu.   

Abstract

We compared in rats with 6-hydroxydopamine (6-OHDA)-induced hemiparkinsonism the content of tumor necrosis factor (TNF)-alpha in the nigrostriatal dopaminergic region of the control side with that of the 6-OHDA-injected experimental side, and explored the effects of 6-OHDA injection combined with the immunosuppressant FK506 treatment (0.5 or 4 mg/kg per day for 2 weeks). The ratios of the concentration of TNF-alpha in the striatum and substantia nigra on the 6-OHDA injection side to that on the control side in the 6-OHDA hemiparkinsonism rats were significantly higher than those in the control rats without 6-OHDA treatment, whereas those in the rats treated with 6-OHDA and FK506 were not significantly different from those in the control rats. Thus FK506 attenuated increased TNF-alpha level in the nigrostriatal dopaminergic region injured by 6-OHDA treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961655     DOI: 10.1016/s0304-3940(00)01275-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  16 in total

1.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention.

Authors:  Malú G Tansey; Melissa K McCoy; Tamy C Frank-Cannon
Journal:  Exp Neurol       Date:  2007-07-17       Impact factor: 5.330

Review 3.  Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.

Authors:  Bin Liu
Journal:  AAPS J       Date:  2006-09-29       Impact factor: 4.009

Review 4.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

Review 5.  Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention.

Authors:  Malú G Tansey; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2009-11-10       Impact factor: 5.996

6.  Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes.

Authors:  Amanda K Ashley; William H Hanneman; Takeshi Katoh; Julie A Moreno; Ashley Pollack; Ronald B Tjalkens; Marie E Legare
Journal:  Toxicol Lett       Date:  2008-11-21       Impact factor: 4.372

Review 7.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  N-Adamantyl Phthalimidine: A New Thalidomide-like Drug That Lacks Cereblon Binding and Mitigates Neuronal and Synaptic Loss, Neuroinflammation, and Behavioral Deficits in Traumatic Brain Injury and LPS Challenge.

Authors:  Shih Chang Hsueh; Weiming Luo; David Tweedie; Dong Seok Kim; Yu Kyung Kim; Inho Hwang; Jung-Eun Gil; Baek-Soo Han; Yung-Hsiao Chiang; Warren Selman; Barry J Hoffer; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-30

10.  Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.

Authors:  Krystyna Gołembiowska; Jadwiga Wardas; Karolina Noworyta-Sokołowska; Katarzyna Kamińska; Anna Górska
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.